Edwards Q1 Results Exceed Expectations
π Edwards Lifesciences reported Q1 revenue of $1.65 billion, beating analyst expectations of $1.6 billion.
π° Earnings per share reached 78 cents, surpassing the forecasted 73 cents.
π Shares rose 4.7% in after-hours trading to close at $83.49 following the strong results.
π The company raised its full-year sales growth guidance to 9%β11%, up from the previous 8%β10%.
π¬ CEO Bernard Zovighian highlighted solid financial performance and strategic progress for the quarter.
π₯ As an Irvine-based medical device company, Edwards continues to deliver strong quarterly results in 2025.
Bullish Signals
- Edwards Lifesciences Corp. shares rose 4.7% to $83.49 after Q1 revenue of $1.65 billion beat analyst expectations of $1.6 billion.
- Earnings per share of 78 cents surpassed the forecast of 73 cents, demonstrating strong profitability.
- The company raised its full-year sales growth guidance to 9% to 11%, up from the previous range of 8% to 10%.
Full Analysis
Edwards Lifesciences Corp. reported first-quarter results that exceeded analyst expectations, driving its shares up 4.7% to $83.49 in after-hours trading with a market capitalization of approximately $46 billion. The Irvine-based medical device company posted revenue of $1.65 billion, surpassing the $1.6 billion forecast, while earnings per share reached 78 cents against a predicted 73 cents. CEO Bernard Zovighian highlighted that the quarter built upon solid financial performance and strategic progress achieved throughout 2025.
Following the strong quarterly performance, Edwards raised its full-year sales growth guidance to between 9% and 11%, an increase from its previous outlook of 8% to 10%. The company attributed this upward revision to stronger-than-expected results in the first quarter, signaling continued confidence in its strategic direction and operational execution.